SAB Biotherapeutics (NASDAQ:SABS) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a strong sell rating to a sell rating in a report published on Saturday morning.

Several other research firms also recently commented on SABS. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Barclays began coverage on shares of SAB Biotherapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price for the company. Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Finally, Citigroup started coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Down 2.0%

SAB Biotherapeutics stock opened at $3.51 on Friday. The firm has a market capitalization of $268.37 million, a PE ratio of -1.66 and a beta of 0.52. The company’s 50-day moving average is $3.69 and its 200-day moving average is $3.84. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Sell-side analysts anticipate that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in SABS. Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the 3rd quarter worth about $22,954,000. Perceptive Advisors LLC boosted its stake in shares of SAB Biotherapeutics by 700.8% during the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of SAB Biotherapeutics during the third quarter valued at about $8,847,000. Woodline Partners LP bought a new stake in shares of SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth about $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.